Press Release FeedGet the RSS feed
Menu

Business Wire

Flatiron Health Brings Three Research Acceptances to WCLC 2026

Business Wire

Real-world evidence on NSCLC treatment patterns and outcomes showcases Flatiron's unified, global oncology engine

NEW YORK, August 19, 2026--Flatiron Health today announced its presence at the IASLC 2026 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, with three research acceptances highlighting real-world evidence that advances precision medicine and treatment optimization in non-small cell lung cancer (NSCLC). The presentations demonstrate how Flatiron's high-quality, longitudinal data reveals clinical insights that shape oncology decision-making across the globe.

"Recent advances have fundamentally transformed treatment options for lung cancers, and our research highlights where and when these novel treatments are having an impact for patients in real-world practice," said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. "Our WCLC research, spanning disease states, biomarker-defined subgroups, and treatment types, illuminates how to translate innovation into practice. By capturing this real-world complexity at scale through our Panoramic Database, we're generating the evidence needed to guide clinicians in a rapidly evolving treatment landscape—enabling them to deliver personalized medicine to any patient that is in front of them."

Flatiron's research at WCLC 2026 underscores the company's position as the gold standard in oncology intelligence, delivering the trusted insights needed to guide the highest-stakes decisions in cancer care and drug development.

Research highlights include:

  • Genomic alterations without approved first-line targeted therapies in patients with NSCLC PD-L1 ≥50% treated with immunotherapy: Real-world evidence revealing treatment patterns and outcomes for patients with high PD-L1 expression who lack approved targeted therapy options, demonstrating how immunotherapy is being deployed in clinical practice and informing precision medicine strategies.

  • Real-world outcomes with chemoradiation and durvalumab consolidation in stage III KRAS G12C–mutant NSCLC in the US: Examining real-world treatment effectiveness and durability of durvalumab consolidation following chemoradiation in patients with stage III KRAS G12C-mutant disease, providing evidence on how emerging targeted approaches are translating to clinical outcomes.

  • Real-world treatment duration and outcomes among patients with early-stage NSCLC receiving adjuvant osimertinib: A retrospective cohort study analyzing treatment patterns, adherence, and survival outcomes in early-stage NSCLC patients receiving adjuvant osimertinib, revealing how precision medicine is reshaping the adjuvant treatment landscape.

  1. IndustrialMitsubishi Electric CorporationMitsubishi Electric Develops New OT Security Solution for Industrial EquipmentCompanies: Mitsubishi ElectricStrengthens product security and enables site-wide visibility for safer and more secure OT environments TOKYO, October 22, 2026--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed a new operational technology (OT) security solution for industrial equipment, leveraging
  2. FinanceArcus Biosciences, Inc.Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common StockCompanies: Jefferies Financial GroupHAYWARD, Calif., October 22, 2026--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,
  3. RetailOptionMetrics Exhibiting at Asia EQDAs APAC options volume increases and retail options trading intensifies overall, leading options data and analytics provider offers derivatives professionals insights on leveraging options data to assess alpha and risk NEW YORK, October 22, 2026--OptionMetrics , the leading historical options data and
  4. ValueAct CapitalValueAct Calls for an Extraordinary General Meeting of Takara Holdings to Strengthen the Board and Hold Incumbent Outside Directors Accountable for Failure to Supervise ManagementSees significant untapped potential in Takara Holdings that more focused strategy and management execution could unlock. Seeks to hold incumbent Outside Directors accountable for the long-term underperformance of the Company and the Board's persistent failure to effectively supervise management. Proposes the election of t
  5. BankingTriad Business BankTriad Business Bank Responds to M&F’s October 19 StatementThe agreement says M&F Bank "will cease to be an independent bank." The meeting moved, but the facts didn't. M&F's Board decided the bank was finished. A new day is here, and Triad is just getting started: it responds to M&F's October 19 statement, corrects the record on its proposal, and keeps M&F alive for its sharehold
  6. FinanceBlackRock Capital Allocation Term TrustBlackRock Capital Allocation Term Trust (BCAT) Announces Results of its Rights OfferingCompanies: BlackRockNEW YORK, October 22, 2026--BlackRock Capital Allocation Term Trust (NYSE: BCAT) (the "Fund") today announced the successful completion of its transferable rights offer (the "Offer") which expired on October 21, 2026 (the "Expiration Date"). The Offer entitled rights holders to subscribe for up to an a